Fortress Biotech, Inc. (FBIO)

NASDAQ: FBIO · Real-Time Price · USD
3.110
+0.360 (13.09%)
At close: Oct 6, 2025, 4:00 PM EDT
3.020
-0.090 (-2.89%)
After-hours: Oct 6, 2025, 7:59 PM EDT
13.09%
Market Cap92.54M
Revenue (ttm)59.30M
Net Income (ttm)-24.05M
Shares Out 29.75M
EPS (ttm)-0.95
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,536,286
Open2.750
Previous Close2.750
Day's Range2.720 - 3.160
52-Week Range1.325 - 4.200
Beta1.76
AnalystsStrong Buy
Price Target16.50 (+430.55%)
Earnings DateNov 13, 2025

About FBIO

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 101
Stock Exchange NASDAQ
Ticker Symbol FBIO
Full Company Profile

Financial Performance

In 2024, Fortress Biotech's revenue was $57.68 million, a decrease of -31.76% compared to the previous year's $84.51 million. Losses were -$55.89 million, -18.61% less than in 2023.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 430.55% from the latest price.

Price Target
$16.5
(430.55% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Fortress Biotech Investigated by the Portnoy Law Firm

LOS ANGELES, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fortress Biotech Inc., ("Slide" or the "Company") (NASDAQ: FBIO) investors that the firm has initiated an investigation into...

5 days ago - GlobeNewsWire

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy

Other symbols: FBIOP
5 days ago - GlobeNewsWire

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Foo...

Other symbols: FBIOP
5 days ago - GlobeNewsWire

Journey Medical Corporation to Participate in September 2025 Investor Conferences

SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on se...

Other symbols: DERM
4 weeks ago - GlobeNewsWire

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term val...

Other symbols: FBIOP
4 weeks ago - GlobeNewsWire

Journey Medical Corporation to Present at the Emerging Growth Conference

SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily f...

Other symbols: DERM
7 weeks ago - GlobeNewsWire

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right...

Other symbols: FBIOP
7 weeks ago - GlobeNewsWire

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

S econd quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June ...

Other symbols: DERM
7 weeks ago - GlobeNewsWire

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that pri...

Other symbols: DERM
2 months ago - GlobeNewsWire

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

Company to host conference call to discuss financial results and provide a corporate update on August 12, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide ...

Other symbols: DERM
2 months ago - GlobeNewsWire

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOT...

Other symbols: DERM
3 months ago - GlobeNewsWire

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical company that pri...

Other symbols: DERM
3 months ago - GlobeNewsWire

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent of body weight differences when treati...

Other symbols: DERM
3 months ago - GlobeNewsWire

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz.

Other symbols: DERM
4 months ago - GlobeNewsWire

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (cos...

Other symbols: FBIOP
4 months ago - GlobeNewsWire

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoi...

Other symbols: FBIOP
5 months ago - GlobeNewsWire

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions ...

Other symbols: DERM
5 months ago - GlobeNewsWire

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

UNLOXCYT™  (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma

Other symbols: CKPT
5 months ago - GlobeNewsWire

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c...

Other symbols: DERM
5 months ago - GlobeNewsWire

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value...

Other symbols: FBIOP
5 months ago - GlobeNewsWire

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that primarily focuses ...

Other symbols: DERM
6 months ago - GlobeNewsWire

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary...

6 months ago - GlobeNewsWire

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and o...

Other symbols: CKPT
6 months ago - GlobeNewsWire

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

Fortress Biotech, Inc. (NASDAQ:FBIO) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, ...

Other symbols: FBIOP
6 months ago - Seeking Alpha

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended D...

Other symbols: DERM
6 months ago - GlobeNewsWire